Integrative Identification of Candidate Protein Targets and Compounds for Dystonia Using Mendelian Randomization, Single-Cell RNA Sequencing, and Network Pharmacology

Abstract

Background Dystonia is a severe neurological disorder with enigmatic pathogenesis. Current treatment options are limited in preventing the disease progression, underscoring the urgent need for new targeted therapeutic agents to develop more effective therapies.